Interference, Opposition, Reexamination and Reissue. 7.3.1 Vertex shall, within ten (10) days of learning of such event, inform Merck of any request for, or filing or declaration of, any interference, opposition, or reexamination relating to Patent Rights. Merck and Vertex shall thereafter consult and cooperate fully to determine a course of action with respect to any such proceeding. Merck shall have the right to review and approve any submission to be made in connection with such proceeding.
Interference, Opposition, Reexamination and Reissue. (a) Either Party shall, within ten (10) days of learning of such event, inform the other Party of any request for, or filing or declaration of, any interference, opposition or reexamination relating to Ambit Licensed Patents, Ambit Program Patents or Joint Program Patents. The Lead Prosecution Party for such patent shall determine a reasonable course of action with respect to any such proceeding, provided that such Party shall consider in good faith the views of the other Party with respect to such proceeding. All responses to or defense against any such request or filing shall be included within the Prosecution efforts above.
Interference, Opposition, Reexamination and Reissue. Merck and Metabasis, shall inform the other of any request for, or filing or declaration of, any interference, opposition, or reexamination relating to the Prior Patents or Collaboration Patents within thirty (30) days of learning of such event. [***] be the lead party in any such interference, opposition, or reexamination relating to the Prior Patents or Collaboration Patents, subject to the provisions of this Section 7.2.4(c). [***] shall have the right to review and consult with [***] regarding any submission to be made in connection with such proceeding. Notwithstanding the foregoing or any other provision of this Agreement to the contrary:
Interference, Opposition, Reexamination and Reissue. 7.4.1 Arvinas shall, within [**] of any of its executive officers learning of such event, inform Pfizer of any request for, or filing or declaration of, any interference, opposition, reissue or reexamination relating to Arvinas Patent Rights which cover the Development or Commercialization of any Compound or Product exclusively licensed by Pfizer hereunder or Joint Patent Rights. Pfizer shall, within [**] of any of its executive officers learning of such event, inform Arvinas of any request for, or filing or declaration of, any interference, opposition, reissue or reexamination relating to Arvinas Patent Rights which cover the Development or Commercialization of any Compound or Product exclusively licensed by Pfizer hereunder or Joint Patent Rights. Pfizer and Arvinas shall thereafter consult and cooperate fully to determine a course of action with respect to any such proceeding. Pfizer shall have the right to review and approve any submission to be made in connection with such proceeding.
Interference, Opposition, Reexamination and Reissue. (a) CytRx shall, within ten (10) days of learning of such event, inform Merck of any request for, or filing or declaration of any interference, opposition, or reexamination relating to Patent Rights, Merck and CytRx shall thereafter consult and cooperate fully to determine a course of action with respect to any such proceeding. Merck shall have the right to review and approve any submission to be made in connection with such proceeding.
Interference, Opposition, Reexamination and Reissue. Either party shall, within ten (10) days of learning of such event, inform the other party of any request for, or filing or declaration of, any interference, opposition, or reexamination relating to ISIS Patent Rights in the Field. MERCK and ISIS shall thereafter consult and cooperate fully to determine a course of action with respect to any such proceeding subject to the following:
Interference, Opposition, Reexamination and Reissue. 12.3.1 Each Party shall, within [*] of learning of such event, inform the other Party of any request for, or filing or declaration of, any interference, derivation proceeding, supplemental examination, post grant review proceeding, inter partes review proceedings, opposition, reissue or reexamination relating to NGM Patents, Collaboration Patents, NP201 Patents or Merck Collaboration Prosecuted Patents being prosecuted or maintained by such Party pursuant to Section 12.2. Merck and NGM shall thereafter consult and cooperate fully to determine a course of action with respect to any such proceeding. The non-prosecuting Party shall have the right to review and approve any submission to be made in connection with such proceeding.
Interference, Opposition, Reexamination and Reissue. If JT becomes aware of any request for, or filing or declaration of any interference, opposition, or reexamination relating to JT Patents in the Gilead Expanded Territory for which JT is responsible for Prosecution, JT shall inform Gilead within thirty (30) days of learning of such event. The Parties shall reasonably cooperate with respect to such interference, opposition, or reexamination. Gilead shall have the right to review and consult with JT regarding any submission to be made in connection with such proceeding. JT shall give Gilead timely notice of any proposed settlement of an interference relating to an JT Patent, and shall not enter into such settlement without Gilead’s prior written consent (such consent not to be unreasonably withheld or delayed).
Interference, Opposition, Reexamination and Reissue. (a) AVEO shall, within ten (10) days of learning of such event, inform MERCK of any request for, or filing or declaration of, any interference, opposition, or reexamination relating to AVEO Patent Rights. MERCK and AVEO shall thereafter consult and cooperate fully to determine a course of action with respect to any such proceeding. MERCK shall have the right to review and approve any submission to be made in connection with such proceeding.
Interference, Opposition, Reexamination and Reissue. (a) A Licensor, within ten (10) days of learning of such an event, shall inform Merck of any request for, or filing or declaration of, any interference, opposition or reexamination relating to Patent Assets. Merck and such Licensor thereafter shall consult and cooperate fully to determine a course of action with respect to any such proceeding and shall agree upon the Parties' rights of review and approval of submissions relating to such proceeding based upon the Parties' relative interests in the relevant portion of Patent Assets.
